OBIO insider trading
HealthcareOrchestra BioMed Holdings, Inc.: insider trade history from SEC Form 4 filings.
About Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Company website: orchestrabiomed.com
OBIO insider activity at a glance
FilingIQ tracks 183 insider transactions for OBIO in filings since Jan 30, 2023. The most recent transaction is dated Oct 1, 2026.
Across the full history, 32 open-market purchases
and 15 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on OBIO insider trades is 54.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest OBIO Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for OBIO?
- FilingIQ tracks 183 Form 4 insider transactions for OBIO (Orchestra BioMed Holdings, Inc.), covering filings from Jan 30, 2023 onwards. 14 of those are dated within the last 90 days.
- Are OBIO insiders net buyers or net sellers?
- Across the full Form 4 history for OBIO, 32 transactions (17%) were open-market purchases and 15 (8%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does OBIO insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is OBIO in?
- Orchestra BioMed Holdings, Inc. (OBIO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $218.80M.
Methodology & sources
Every OBIO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.